1 / 4

Sudden Cardiac Death in Heart Failure Trial

SCD-HeFT. Sudden Cardiac Death in Heart Failure Trial. Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy. SCD-HeFT. 2,521 patients with moderately symptomatic CHF (NYHA Class II or III) and LVEF ≤35% Randomized, double-blind, multicenter.

aspasia
Télécharger la présentation

Sudden Cardiac Death in Heart Failure Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SCD-HeFT Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy

  2. SCD-HeFT 2,521 patients with moderately symptomatic CHF (NYHA Class II or III) and LVEF ≤35% Randomized, double-blind, multicenter Conventional CHF Treatment + Placebo Conventional CHF Treatment + ICD Single lead implantable cardioverter defibrillator programmed for ventricular fibrillation (VF) treatment only • Conventional CHF Treatment + Amiodarone • Antiarrhythmic agent • 800 mg Week 1, 400 mg Week 2-4 • Chronic therapy: • 200 mg/day if <150 lbs • 300 mg/day if 150-200 lbs • 400 mg/day if >200 lbs Treatment • Endpoints (median 45.5 months): All-cause mortality Presented at ACC Scientific Sessions 2004

  3. SCD-HeFT All-cause mortality at 5 years Amiodarone vs placebo HR 1.06, p=0.529 ICD vs placebo HR 0.77, p=0.007 • Medication use at end of follow-up included 72% ACE-inhibitors, 78% beta-blockers, 80% loop diuretics, and 55% ASA • Prior duration of CHF was 24.5 months at baseline • No difference in all-cause mortality between amiodarone and placebo arm • Mortality was lower in ICD arm vs placebo % Mortality Presented at ACC Scientific Sessions 2004

  4. SCD-HeFT • Among patients with NYHA Class II or Class III CHF and reduced left ventricular ejection fraction, treatment with an implantable ICD was associated with a reduction in all-cause mortality compared with placebo, but there was no difference between amiodarone and placebo • Secondary endpoint data not yet reported

More Related